Related Content
- Big Molecule WatchDecember 9, 2024
Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2024-2025
- Big Molecule WatchDecember 7, 2024
Biocon Announces FDA Approval of Ustekinumab Biosimilar
- Big Molecule WatchDecember 4, 2024
Update on Pending Denosumab BPCIA Litigations
- Big Molecule WatchNovember 27, 2024
European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar
- Big Molecule WatchNovember 19, 2024
FDA approves CAR-T Cell Therapy for Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- Big Molecule WatchNovember 18, 2024
Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar
- Big Molecule WatchNovember 14, 2024
Celltrion Launches STEQEYMA (ustekinumab) in Germany and the Netherlands
- Big Molecule WatchNovember 7, 2024
FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar
- Awards and RankingsSeptember 9, 2024
Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year